CUTANEOUS DRUG-INDUCED LUPUS ERYTHEMATOSUS: CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS AND UPDATE ON NEW ASSOCIATED DRUGS

Service de dermatologie et allergologie, faculté de médecine Sorbonne Université, Hôpital Tenon, AP–HP, Paris, France

Cutaneous drug-induced lupus erythematosus (CDILE) is a lupus-like syndrome that typically resolves after the discontinuation of the offending drug. The study highlights the evolving pharmacoepidemiology of CDILE, noting that older drugs are being replaced by newer ones, including anti-TNFα and checkpoint inhibitors. A literature review identified 109 drugs associated with CDILE in 472 patients, emphasizing the need for larger studies and validated classification criteria to better understand the implications of these drugs. Management strategies include drug withdrawal and potential topical treatments, with a focus on patient outcomes.